Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Downgrades Salesforce to Neutral, Lowers Price Target to $150

Baird analyst Rob Oliver downgrades Salesforce (NYSE:CRM) from Outperform to Neutral and lowers the price target from $200 to $150.

byBenzinga Newsdesk

December 8, 2022

1 minute read

Baird analyst Rob Oliver downgrades Salesforce (NYSE:CRM) from Outperform to Neutral and lowers the price target from $200 to $150.

Albireo Pharma Sells Bylvay-Associated PRV For $105M

By Vandana Singh

Today, 8:28 AM

Albireo Pharma Inc (NASDAQ:ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV…

ALBO

Secretary Of State Blinken Says U.S. Has ‘Credible’ Information Russia May Use ‘Chemical Agents’ In Ukraine

By Benzinga Newsdesk

Today, 8:28 AM

-Reuters

ATHX

Citigroup Maintains Neutral on Live Nation Entertainment, Raises Price Target to $98

By Benzinga Newsdesk

Today, 8:28 AM

Citigroup maintains Live Nation Entertainment (NYSE:LYV) with a Neutral and raises the price target from $94 to $98.

LYV

Merck And Ridgeback’s Molnupiravir, An Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant In Vitro Studies

By Benzinga Newsdesk

Today, 8:28 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced data from six preclinical studies demonstrating that molnupiravir, an investigational oral antiviral

MRK

Baird Downgrades Salesforce to Neutral, Lowers Price Target to $150

Related Posts

Albireo Pharma Sells Bylvay-Associated PRV For $105M

Secretary Of State Blinken Says U.S. Has ‘Credible’ Information Russia May Use ‘Chemical Agents’ In Ukraine

Citigroup Maintains Neutral on Live Nation Entertainment, Raises Price Target to $98

Merck And Ridgeback’s Molnupiravir, An Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant In Vitro Studies